Your browser does not support JavaScript!

Δημοσιεύσεις

Τρέχουσα Εγγραφή: 2 από 2

Πίσω στα Αποτελέσματα Προηγούμενη σελίδα
Επόμενη σελίδα
Προσθήκη στο καλάθι
[Προσθήκη στο καλάθι]
Τίτλος Optimization of the Enrichment of Circulating Tumor Cells for Downstream Phenotypic Analysis in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-1 Immunotherapy
Συγγραφέας Papadaki, Maria A.
Συγγραφέας Sotiriou, Afroditi I.
Συγγραφέας Vasilopoulou, Christina
Συγγραφέας Filika, Maria
Συγγραφέας Aggouraki, Despoina
Συγγραφέας Tsoulfas, Panormitis G.
Συγγραφέας Apostolopoulou, Christina A.
Συγγραφέας Rounis, Konstantinos
Συγγραφέας Mavroudis, Dimitrios
Συγγραφέας Agelaki, Sofia
Περίληψη The current study aimed at the optimization of circulating tumor cell (CTC) enrichment for downstream protein expression analyses in non-small cell lung cancer (NSCLC) to serve as a tool for the investigation of immune checkpoints in real time. Different enrichment approaches—ficoll density, erythrolysis, their combination with magnetic separation, ISET, and Parsortix—were compared in spiking experiments using the A549, H1975, and SKMES-1 NSCLC cell lines. The most efficient methods were tested in patients (n = 15) receiving immunotherapy targeting programmed cell death-1 (PD-1). Samples were immunofluorescently stained for a) cytokeratins (CK)/epithelial cell adhesion molecule (EpCAM)/leukocyte common antigen (CD45), and b) CK/programmed cell death ligand-1 (PD-L1)/ indoleamine-2,3-dioxygenase (IDO). Ficoll, ISET, and Parsortix presented the highest yields and compatibility with phenotypic analysis; however, at the patient level, they provided discordant CTC positivity (13%, 33%, and 60% of patients, respectively) and enriched for distinct CTC populations. IDO and PD-L1 were expressed in 44% and 33% and co-expressed in 19% of CTCs. CTC detection was associated with progressive disease (PD) (p = 0.006), reduced progression-free survival PFS (p = 0.007), and increased risk of relapse (hazard ratio; HR: 10.733; p = 0.026). IDO-positive CTCs were associated with shorter PFS (p = 0.039) and overall survival OS (p = 0.021) and increased risk of death (HR: 5.462; p = 0.039). The current study indicates that CTC analysis according to distinct immune checkpoints is feasible and may provide valuable biomarkers to monitor NSCLC patients treated with anti-PD-1 agents.
Γλώσσα Αγγλικά
Θέμα CTCs
Circulating tumor cells
ICIs
IDO
ISET
Immune checkpoint inhibitors
Immune evasion
Immunotherapy
Indoleamine-2,3-dioxygenase
Liquid biopsy
NSCLC
Non-small cell lung cancer
PD-L1
Parsortix
Programmed cell death-1 ligand
Ημερομηνία έκδοσης 2020-06-12
Συλλογή   Σχολή/Τμήμα--Ιατρική Σχολή--Τμήμα Ιατρικής--Δημοσιεύσεις
  Τύπος Εργασίας--Δημοσιεύσεις
Σημειώσεις European Commission Horizon 2020-Research and Innovation Program H2020-FETOPEN-1-2016-2017 (GA NUMBER-737212-Capturing non-Amplified Tumor Circulating DNA with Ultrasound Hydrodynamics (CATCH-U-DNA)).
Δικαιώματα χρήσης
Creative Commons License
Μόνιμη Σύνδεση https://elocus.lib.uoc.gr//dlib/f/b/3/metadata-dlib-1607327986-856730-23506.tkl Bookmark and Share
Εμφανίσεις 801

Ψηφιακά τεκμήρια
No preview available

Κατέβασμα Εγγράφου
Προβολή Εγγράφου
Εμφανίσεις : 4